# Pioglitazone

## Actos 30mg

| TAH Drug Code      | [OACT3](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OACT3                                                                                                                                                                                                                                                                                                 |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Monotherapy or in combination with sulphonylureas, metformin or insulin in patients with type II diabetes.                                                                                                                                                                                                                                                            |
| Dosing             | 15-30 mg once daily, maximum: 45 mg/day.                                                                                                                                                                                                                                                                                                                              |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                         |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                         |
| Contraindications  | Type 1 diabetes, diabetic ketoacidosis. Active hepatic disease or ALT levels > 2.5 times the upper limit of normal. NYHA class III or IV heart failure.                                                                                                                                                                                                               |
| Adverse Effects    | Edema, upper respiratory tract infection, headache, myalgia. Cardiovascular: Edema (4.8% to 15.3% ) Endocrine metabolic: Weight gain Hematologic: Anemia (less than or equal to 2% ) Musculoskeletal: Fracture of bone (5.1% ), Myalgia (5.4%) Neurologic: Headache (9.1% ) Respiratory: Pharyngitis (5.1% ), Sinusitis (6.3% ), Upper respiratory infection (13.2% ) |
| Pregnancy          | No (Limited) Human Data â€“ Animal Data Suggest Moderate Risk                                                                                                                                                                                                                                                                                                           |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                         |
| More Info          | [UpToDate](https://www.uptodate.com/contents/pioglitazone-drug-information)                                                                                                                                                                                                                                                                                           |

